PT  - JOURNAL ARTICLE
AU  - Duchek, Jan
AU  - Havasi, Balazs
TI  - Analysis of Particulate Matter in Liquid Finished Dosage Forms
AID  - 10.5731/pdajpst.2017.008292
DP  - 2018 Jan 01
TA  - PDA Journal of Pharmaceutical Science and Technology
PG  - pdajpst.2017.008292
4099  - http://journal.pda.org/content/early/2018/05/25/pdajpst.2017.008292.short
4100  - http://journal.pda.org/content/early/2018/05/25/pdajpst.2017.008292.full
AB  - Pharmacopoeias recognize particulate matter as a common phenomenon. The current regulatory requirements relating to particulate matter in parenterals state that solutions for injections or infusions are clear and “practically” (or “essentially”) free from (“readily detectable”) particles when examined under defined conditions of illumination. Pharmaceutical companies are required to know their processes and have them under control. In order to control and reduce the potential influx of particulate matter, Novartis Technical Operations in Unterach developed a particle life cycle program that involved an establishment of a dedicated particle laboratory operating under clean room conditions. The analytical capabilities of this particle laboratory were crucial for the characterization of particles and supported identification of potential sources of particulate matter. After implementation of this program and respective actions, product and process understanding significantly improved. This resulted in a decrease of reject rates, AQL (Acceptable Quality Limit) failures, and corresponding batch rejections, thereby increasing the availability of Novartis products from Unterach for the patients. The main objective of this article is to show the detailed particle characterization approach including Quality by Design (QbD), methods, and equipment. Examples from projects and particulate matter investigations are presented.